Malamet 1984.

Methods	Double‐blind cross‐over randomized placebo‐controlled trial Placebo, nifedipine (2 10‐mg capsules 3× daily), and dazoxiben (100 mg 4× daily) 10‐Week study with 6 treatment periods 2‐Week single‐blind placebo run‐in period 3 2‐week double‐blind cross‐over treatment periods (separated by 1‐week single‐blind washout periods)
Participants	13 patients ‐ 7 female and 2 male Mean age 34.6 ± 4.0 years, range 21 to 55 Duration of Raynaud's 11.4 ± 2.6 years, range 1 to 22 8 patients with secondary Raynaud's (associated with connective tissue disease), 1 with primary Raynaud's
Interventions	Placebo Nifedipine (2 10‐mg capsules 3× daily) Daxoziben (100 mg 4× daily)
Outcomes	Number of Raynaud's attacks Severity of attacks (3‐point scale) Pain intensity (VAS scale) Duration of episodes (minutes)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Evidence insufficient for judgement of risk
Allocation concealment (selection bias)	Unclear risk	Evidence insufficient for judgement of risk
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participant diary used to record subjective assessments
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data
Selective reporting (reporting bias)	Low risk	None detected
Other bias	Low risk	1‐Week single‐blind washout period between cross‐over phases